Anthony G. Letai, MD, PhD, sworn in as NCI Director
Anthony G. Letai, MD, PhD, was sworn in on September 29, 2025, as director of the National Cancer Institute (NCI), part of the
Anthony G. Letai, MD, PhD, was sworn in on September 29, 2025, as director of the National Cancer Institute (NCI), part of the
The US Food and Drug Administration (FDA) has granted a De Novo Classification Request for the CytoCell KMT2A Breakapart FISH Probe Kit PDx,
In this podcast episode recorded at the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Megan Melody, MD, from Tampa
In this video interview from the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Asfand Yar Cheema, MD, resident physician
The study was led by Paula Rodríguez-Otero, MD, PhD, a consultant hematologist at Clínica Universidad de Navarra, on September 19, 2025, who presented
In patients with high-risk multiple myeloma, maintenance therapy with belantamab, pomalidomide, and dexamethasone (BPD) demonstrated encouraging activity and a manageable safety profile, according
Daratumumab raises early infection risks in patients treated with multiple myeloma, according to an oral abstract presented on September 17, 2025, at the
In this video interview from the Thirteenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2025), Reem Karmali, MD, an associate professor
Patients with polycythemia vera (PV) who received GLP-1a therapy had markedly better outcomes than patients who did not, according to a retrospective study
Achievement of early measurable residual disease (MRD) negativity under assessment with next-generation sequencing (NGS) is associated with durable remissions in patients with newly